Review
Copyright ©The Author(s) 2023.
World J Clin Oncol. Feb 24, 2023; 14(2): 40-68
Published online Feb 24, 2023. doi: 10.5306/wjco.v14.i2.40
Figure 3
Figure 3 Management of hereditary cancer syndromes. PARPi: Poly (ADP-ribose) polymerase inhibitors; TMB: Tumor mutation burden; HIF-2α: Hypoxia inducible factor-2α; VHL: von Hippel-Lindau; mTOR: Mechanistic target of rapamycin; MAPK: Mitogen-activated protein kinase signaling pathway; MEK: Mitogen-activated protein kinase; VEGFR: Vascular endothelial growth factor receptor; SMO: Smoothened; CMMRD: Constitutional mismatch repair deficiency syndrome.